FeesSafety
Pluang+

Invivyd to announce interim Phase 3 trial results for COVID-19 antibody VYD2311 on Nov 23

Company Fundamentals
22 Nov 2026, 23:20 WIB
GlobeNewsWire
View Source
Neutral
Invivyd to announce interim Phase 3 trial results for COVID-19 antibody VYD2311 on Nov 23

Invivyd, Inc. will hold a conference call on November 23, 2026, to announce interim results from its ongoing Phase 3 DECLARATION clinical trial of VYD2311, a novel monoclonal antibody for COVID-19. The company aims to provide new prophylactic and therapeutic options with VYD2311, which is designed for easier administration and targets current virus variants. Results will be shared via press release and webcast, with a replay available on Invivyd's investor website. This update is important as it could impact the development and regulatory progress of a promising COVID-19 treatment candidate.

Invivyd's upcoming announcement on November 23, 2026, provides context for health-sector market activity on Pluang as of Nov 23, 2026 03:02 WIB. Among 150 priced US health stocks, 31 rose and 117 fell today. Notable movers include RXRX at USD 2.45 with a -9.93% change, TXG at USD 51.80 down 9.72%, and TMDX at USD 85.25 down 9.33%.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
24 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
28 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
33 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
33 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
33 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App